Table 2.
Experiment models for exploring the roles of TLR9 in cardiometabolic disorders
| Mice strain | Model (feeding) | Duration of feeding | Agonist | Antagonist | Role | Ref |
|---|---|---|---|---|---|---|
| Obesity | ||||||
|
Tlr9-/- (B6.129P2-Tlr9tmAki) |
HFD, 60 kcal% fat | 12 weeks | - | - | promotive | [10] |
| C57BL/6 | 12 weeks | - | iODN2088 for 12 weeks | |||
|
Tlr9+/+ bone marrow in Tlr9-/- (B6.129P2-Tlr9tmAki) |
12 weeks | - | - | |||
|
Tlr9-/- (C57BL/6J-Tlr9M7Btlr) |
HFD, 60 kcal% fat | 15 weeks | - | - | promotive | [11] |
| C57BL/6 | 10 weeks | - | IRS954 for 3 weeks | |||
| C57BL/6J | Normal chow diet | 8 days | CpG-ODN2395 for 8 days | - | ||
| C57BL/6J | HFD, 40 kcal% fat | 12 weeks | - | - | - | [12] |
| ob/ob | Standard chow diet | 12 weeks | - | - | ||
|
Tlr9-/- (B6.129P2-Tlr9tmAki) |
HFD, 60 kcal% fat | 8-10 weeks | - | - | protective | [13] |
| Atherosclerosis | ||||||
|
Tlr9-/-Apoe-/- (C57BL/6 background) |
WTD, 21% fat, 0.2% cholesterol +Ang II-infusion for 4 weeks |
12 weeks | - | - | promotive | [19] |
|
Tlr9-/-Apoe-/- (C57BL/6 background) |
12 weeks | - | iODN2088 for 4 weeks | |||
|
Tlr9+/+ bone marrow in Tlr9-/-Apoe-/- (C57BL/6 background) |
12 weeks | - | - | |||
|
Apoe*3Leiden transgenic mice |
WTD + cuff placement for 2 weeks |
5 weeks | - | TLR7/9 dual antagonist for 2 weeks | promotive | [22] |
|
Apoe-/- (C57BL/6 background) |
Cholesterol rich diet, 21% fat and 1.25% cholesterol | 8 weeks | CpG-ODN1826 for 7 weeks | - | promotive | [26] |
| Apoe-/- | HFD, 21% fat and 0.15% cholesterol | 6 weeks | CpG-ODN1585 for 5 weeks | - | promotive | [20] |
|
Tlr9-/-Apoe-/- (C57BL/6 background) |
HFD, 21% fat and 0.15% cholesterol | 12 weeks | - | - | protective | [27] |
|
Apoe-/- (C57BL/6 background) |
8 weeks | CpG-ODN1668 for 8 weeks | - | |||